Related Experiment Videos
Dextrothyroxine treatment of phosphorylase-kinase deficiency glycogenosis in four boys
Insights
Sodium dextrothyroxine (D-T4) effectively treated glycogen storage disease type IXb in young boys. The therapy normalized liver size and improved biochemical markers, offering a promising treatment option.
Area of Science:
- Biochemistry
- Pediatric Endocrinology
- Metabolic Disorders
Background:
- Glycogen storage disease type IXb (GSD IXb) is an X-linked disorder characterized by phosphorylase-kinase deficiency.
- Hepatomegaly and biochemical abnormalities are common in affected children.
- Long-term outcomes for GSD IXb remain unclear.
Purpose of the Study:
- To evaluate the efficacy of sodium dextrothyroxine (D-T4) in treating GSD IXb in young boys.
- To assess the impact of D-T4 on liver size and biochemical parameters.
Main Methods:
- Four boys with GSD IXb received D-T4 (0.165 mg/kg/day) for 6 months.
- Liver size, serum GOT, GPT, triglycerides, and glucose levels were monitored.
- Phosphorylase-kinase activity was assessed in erythrocytes and liver tissue.
Main Results:
- D-T4 treatment led to complete normalization of liver size.
- Significant decreases in serum GOT, GPT, and triglycerides were observed.
- Mild asymptomatic hypoglycemia was corrected.
Conclusions:
- D-T4 therapy appears effective in reducing hepatomegaly and correcting biochemical abnormalities in GSD IXb.
- Dextrothyroxine may be a beneficial treatment option for GSD IXb, especially given the undefined adult outcomes.
Abstract:
Four boys, aged 2 years 5 months to 3 years 7 months, with large hepatomegaly due to phosphorylase-kinase deficiency glycogenosis, were given a trial of sodium dextrothyroxine (D-T4) at a mean dose of 0.165 mg/kg/day for an average period of 6 months. Phosphorylase-kinase was undetectable in the haemolysates of erythrocytes (3 patients) or in the liver (one patient) before, and still undetectable in the haemolysates of the four patients during treatment, thus pointing to X-linked phosphorylase-kinase deficiency glycogen storage disease (GSD IXb). D-T4 administration resulted in complete normalization of liver size, decrease of serum GOT (p less than 0.02), GPT (p less than 0.05) and triglycerides (p less than 0.01) to normal values, as well as correction of mild asymptomatic hypoglycemia (p less than 0.01). As long as the outcome of type IXb glycogenosis in adult life remains undefined, dextrothyroxine therapy seems an effective means of reducing liver size and correcting part of the biochemical abnormalities of the disease.